
Evommune, Inc.: stock overview
Price
$7.04
November 20, 2026Market cap $291M
What Ploutos Investor adds for Evommune
Part of Ploutos Investor, €9.99 a month
- The full history: 2 fiscal years, from 2024
- The estimated fair value, with its range and its certainty
- The full analysis, 18 a month
- More questions to the chat on its filings
- Excel with every year
- An email when it reports, changes its dividend or an officer buys
Sign in with a free account to see the last 5 fiscal years.
In short
Evommune had revenue of $0 over the last 12 months and a net loss of $113M. It holds more cash than debt, by $168M. It pays no dividend.
From its SEC filings (latest fiscal year to December 31, 2025) and the price of November 20, 2026.
Its SEC filings- Market cap
- $291M
- 41.35M shares
- P/E
- –
- Revenue, 12 months
- $0
- +85.7% a year over 1 years
- Net margin
- -529.8%
Worth knowing
What a holder would want to hear from the company's SEC filings of the last three years. Each with its filing, without comment.
2 fiscal years in figures
Each fiscal year's figures as the company filed them, and the share price at its end.
Key figures
The company's current figures in five groups. Each term is explained behind its ⓘ.
Valuation
- Market cap
- $291M
- Enterprise value
- $123M
- P/E
- –
- EV / EBIT
- –
- EV / Revenue
- –
- P/B
- 1.2
- FCF yield
- –
- Earnings yield
- –
Profitability
- Operating margin
- -623.6%
- Net margin
- -529.8%
- ROIC
- -56.3%
- ROIC, 5-year average
- -31.2%
- ROE
- -66.1%
Growth
- Revenue, yearly change
- +85.7%
- EPS, yearly change
- –
- FCF, yearly change
- –
- Revenue, average a year
- +85.7%
The yearly change compares FY2025 with FY2024.
Balance sheet
- Cash
- $169M
- Total debt
- $8.2M
- Of which operating leases
- $7.4M
- Net cash
- $168M
- Net debt / EBITDA
- –
- Interest cover
- –
- Current ratio
- 8.52
Balance sheet of September 30, 2026.
Returns to shareholders
- Dividend yield
- 0.00%
- Buybacks
- –
- Total returned
- 0.00%
- Shares, yearly change
- +2,221.6%
The company at the SEC
How it is registered and when its fiscal year ends.
- Name at the SEC
- Evommune, Inc.
- CIK
- 2044725
- Exchange
- NYSE
- Industry (SIC)
- 2834 · Pharmaceutical Preparations
- Fiscal year ends
- December 31
- Latest annual report
- December 31, 2025
- Reporting currency
- USD
- Shares
- 41.35M
Other companies: Healthcare
The largest companies of the same sector, each with its own page.
- LLYEli Lilly and Company+0,00%Compare with EVMN
- JNJJohnson & Johnson+0,00%Compare with EVMN
- ABBVAbbVie+0,00%Compare with EVMN
- UNHUnitedHealth+0,00%Compare with EVMN
- MRKMerck & Company+0,00%Compare with EVMN
- AMGNAmgen+0,00%Compare with EVMN
- TMOThermo Fisher Scientific+0,00%Compare with EVMN
- ABTAbbott Laboratories+0,00%Compare with EVMN
The full analysis
What do Evommune's filings show?
These are Evommune's figures. The full Ploutos AI analysis reads everything the company has filed and shows what stands behind it, with a source for every figure.
- A fair value range built from the filings
- Earnings quality, debt and red flags
- Insider and institutional moves
- The case for and the case against
What is EVMN's market cap?
Evommune, Inc.'s market cap is $291M, at a price of $7.04 on November 20, 2026 and 41.35M shares.
How much revenue does EVMN have?
Evommune had revenue of $0 over the last 12 months. Over the last 1 years it changed by +85.7% a year on average.
Does EVMN pay a dividend?
No. Evommune paid no regular dividend over the last 12 months.
Where do the figures come from?
From Evommune, Inc.'s SEC filings (10-K and 10-Q) and the share price. They hold no analyst estimates and no score, and they are not a recommendation.
Related pages
The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.
The figures come from the company's SEC filings and the share price, and describe what it has reported. They are not a score or a fair value.